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ABSTRAK  
 
Pengenalan:  
Vascular endothelial growth factor (VEGF) dipercayai memainkan peranan dalam patogenesis dan 
tahap keterukan diabetik retinopati (DR) di kalangan pesakit diabetik. Oleh itu, dengan mengkaji 
paras VEGF dalam serum darah dan air mata pesakit diabetik akan memberikan kita gambaran 
yang lebih mendalam tentang peranan VEGF dalam patogenesis DR.  
 
Objektif: 
Objektif kajian ini adalah untuk menilai paras kandungan VEGF dalam serum darah dan air mata 
di kalangan pesakit diabetes mellitus (DM) jenis ke 2 dengan pelbagai tahap DR. Kajian ini juga 
akan melihat kolerasi paras VEGF di antara serum darah dan air mata di kalangan pesakit ini. 
 
Kaedah: 
Kajian keratan rentas telah dijalankan di salah satu hospital tertiari di Malaysia iaitu di Hospital 
Universiti Sains Malaysia (USM) di antara Ogos 2016 dan Mei 2018. Kajian ini telah melibatkan 
pesakit DM jenis ke 2 dengan pelbagai tahap DR [tiada DR, retinopati tidak proliferatif (NPDR), 
retinopati proliferative (PDR)]. Sampel air mata diambil menggunakan kertas Schirmers manakala 
sampel serum darah diambil dari salur darah vena. Paras VEGF di dalam serum darah dan air mata 
diukur menggunakan teknik assay enzim imunosorben.  
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Keputusan: 
Sejumlah 88 pesakit DM jenis ke 2 (tiada DR: 30 pesakit, NPDR: 28 pesakit, PDR: 30 pesakit) 
terlibat dalam kajian. Kajian ini telah menunjukan purata VEGF air mata  lebih tinggi yang 
signifikan dalam kumpulan NPDR dan PDR (114.9 SD 8.6 pg / mL dan 149.5 SD 10.4 pg / mL 
mengikut aturan) berbanding pesakit yang tiada DR (41.2 SD 11.3 pg / mL, p < 0.001). 
Walaubagaimanapun, tiada perbezaan signifikan purata VEGF serum darah di kalangan tiga 
kumpulan ini. Kajian ini juga mendapati terdapat korelasi yang sederhana paras VEGF di antara 
serum darah dan air mata (p = 0.015, r = 0.263).  
 
Kesimpulan: 
Di kalangan pesakit DM jenis ke 2, paras VEGF air mata di kalangan pesakit DR adalah lebih 
tinggi berbanding dengan pesakit yang tidak mempunyai DR. Paras VEGF air mata juga didapati 
ada kaitan dengan tahap keterukan DR. Selain itu kajian ini juga menunjukan terdapat korelasi 
yang sederhana paras VEGF antara serum dan air mata. Paras VEGF di dalam air mata mungkin 
memainkan peranan dalam meramalkan tahap keterukan DR dan membuka jalan bagi penilaian 
DR secara bukan invasif. Kajian kohort yang lebih besar diperlukan untuk penilaian selanjutnya. 
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ABSTRACT 
 
Introduction  
Vascular endothelial growth factor (VEGF) has been postulated to play a role in the pathogenesis 
and progression of diabetic retinopathy (DR). Thus, detection of VEGF level in ocular tissue may 
perhaps provide insight into a role of VEGF in pathogenesis of DR.  
 
Objective:  
The objective of this study was to evaluate the VEGF in serum and tears between different type of 
DR severity among type 2 diabetes mellitus (DM) patients and to determine the correlation between 
serum and tears VEGF levels. 
 
Methods: 
A comparative cross-sectional study was conducted at a tertiary hospital in Malaysia, Hospital 
Universiti Sains Malaysia (USM) between August 2016 and May 2018 involving type 2 DM 
patients with different status of DR [no DR, non-proliferative DR (NPDR), proliferative DR 
(PDR)]. Tear samples were collected using no.41 Whatman filter paper (Schirmer’s strips) and 5 
mls of blood sample were drawn by venous puncture. VEGF levels in tears and serum were 
measured by enzyme-linked immunosorbent assay.  
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Results:  
A total of 88 type 2 DM patients (no DR: 30 patients, NPDR: 28 patients, PDR: 30 patients) were 
included into the study. Mean tear VEGF were significantly higher in NPDR and PDR groups 
(114.9 SD 8.6 pg/mL and 149.5 SD 10.4 pg/mL respectively) as compared to no DR (41.2 SD 11.3 
pg/mL, p < 0.001). There was no significant difference of mean serum VEGF between the three 
groups. There was a fair correlation between serum and tears VEGF (p = 0.015, r = 0.263).  
 
Conclusion: 
Among type 2 DM patients, VEGF levels in tears were higher amongst patients with DR compared 
to those without DR. Tear VEGF levels were also significantly associated to the severity of DR. 
There was a fair correlation between serum and tears VEGF. Detection of VEGF in tears is a good 
non-invasive predictor test for severity of DR. A large cohort study is needed for further evaluation.  
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INTRODUCTION 
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1.1 Diabetes Mellitus  
Diabetes mellitus (DM) was first described by the ancient Egyptian around 1500 B.C. and only 
later in 1776 Matthew Dobson successfully demonstrated the evidence of the high glucose 
concentration in the urine in diabetic patients (Polonsky, 2012).  Despite many advances in the 
medical field, DM remains as an important global public health concern (Wild et al., 2004). It 
is more alarming as diabetes is projected to affect approximately 7.7% of the world’s 
population (439 million adults) by 2030 (Shaw et al., 2010).  
 
The International Diabetes Federation (IDF) estimates that the prevalence of DM in South East 
Asia will increase by two folds by the year 2025 (IDF and WHO, 2000). According to The 
World Health Organization (WHO), it is estimated by the year of 2030, Malaysia would have 
a total of 2.48 million people with diabetes (WHO, 2005). In 1986, the first National Health 
and Morbidity Survey I (NHMS I) reported a DM prevalence of 6.3%. This had risen to 8.3% 
in the NHMS II’s 1996 report. Recently, the NHMS 2011 reported diabetes prevalence figures 
of 15.2% and 20.8% for adults above the age of 18 and 30 years old respectively in Malaysia 
(NHMS IV, 2011). NHMS I and II involved subjects aged above 30 years while the NHMS III 
was conducted among subjects above 18 years of age (Feisul and Soraya, 2013). Among adults 
above the age of 18 years old, the prevalence was highest among Indians (24.9%) followed by 
Malays (16.9%) and Chinese (13.8%) (NHMS IV, 2011).  
 
The prevalence of type 2 DM is increasing in the young with 2% and 4.9% of those between 
ages 18-19 years and 20-24 years respectively (NHMS IV, 2011). In terms of diabetes control, 
only 23.8% of patients in primary care and 12.7% in tertiary institutions were able to achieve 
their specified glycaemic targets (Feisul and Soraya, 2013; Mafauzy et al., 2016). Up to 21.4% 
of type 2 DM patients in primary care were on insulin compared to 65.4% in tertiary institutions 
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(Feisul and Soraya, 2013; Mafauzy et al., 2016). In years to come, it is anticipated that a 
proportionate increment in diabetic retinopathy (DR) is unavoidable. 
 
1.2 Effect of Diabetes Mellitus 
DM is a complex and multisystem disease with various end organ complications. This damage 
is referred to as diabetic related complications. Generally, the detrimental effects of 
hyperglycemia are divided into macrovascular and microvascular complications (Patel et al., 
2012). Indeed, there is increasing evidence that micro- and macro-vascular disease share 
similar risk factors (Liao et al., 2004; Nguyen et al., 2007) and possibly even a common 
pathophysiological basis (Krentz et al., 2007; Stokes et al., 2005). Hyperglycemia can promote 
vascular complications by multiple postulated mechanisms. Elevated glucose can foster the 
formation of advanced glycation end products (AGEs) protein cross-linking and reactive 
oxygen species formation which damages vessel endothelial cell wall (Piga et al. 2007). This 
causes the thickening of capillary basement membranes and arteriolar hyalinosis. 
Hyperglycemia can also activate multiple pro-inflammatory target genes in endothelial cells 
and stimulate oxidative stress (Otsuka et al. 2005). This has been strongly implicated in the 
endothelial cell proliferation and formation of atherosclerosis.  
 
1.2.1 Systemic Effects 
The fundamental pathological mechanism in macrovascular disease is the process of 
atherosclerosis, which leads to narrowing of arterial walls throughout the body (Michael, 
2008). Atheroma formation is thought to result from chronic inflammation of the endothelial 
lining of vessel wall (Hansson, 2005). In response to endothelial injury and inflammation, 
oxidized lipids from low density lipoprotein particles accumulate in the endothelial wall of 
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arteries (Michael, 2008). The net result of this process is the formation of a lipid-rich 
atherosclerotic plaque which impairs blood flow and cause vascular infarction (Boyle, 2007).  
 
Type 2 DM increases the risk of cardiovascular disease which can present as angina, 
myocardial infractions, congestive cardiac failure and sudden death (Martín-Timón, et al. 
2014). This accounts for up to two-third of deaths in type 2 DM (Carnethon, et al. 2010). In 
addition, type 2 DM, independent of chronic heart disease (CHD) may lead to diabetic 
cardiomyopathy. Hyperglycemia seems to be central to the pathogenesis of diabetic 
cardiomyopathy. Elevared blood glucose trigger a series of maladaptive stimuli that result in 
myocardial fibrosis and collagen deposition (Aneja, et al. 2008). It has been shown that 
hyperglycemia and its related consequences is an important risk for CHD and related mortality 
(DCCT, 1993; Stamler et al., 1993; Adlerberth et al., 1998). 
 
In addition, patients with diabetes are also at high risk of developing microvascular 
complications. Pathological changes in the diabetic microvasculature will alter organ perfusion 
(Orasanu and Plutzky, 2009). This includes organs heavily dependent on their microvasculature 
supply, namely the retina, kidneys, and peripheral nervous system. Diabetic nephropathy is a 
major cause of chronic kidney disease (CKD) contributing to 57% of patients requiring dialysis 
in 2007 in Malaysia (Lim et al., 2007). Diabetic nephropathy is also a major risk factor for 
cardiovascular morbidity and mortality (Alzaid 1996). This cardiovascular risk increases in a 
continuous fashion along with progression of nephropathy from normal to overt proteinuria 
levels (Mattock, et al. 1992). In a large study, the reduction of albuminuria with therapeutic 
interventions resulted in protection against cardiovascular disease as well as the development 
of progressive renal impairment (UKPDS, 1998). 
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Other microvascular complications like diabetic peripheral neuropathy may be asymptomatic 
in a large proportion of cases (Boulton et al., 2005). Neuropathy causes loss of protective 
sensation and loss of coordination of muscle groups in the foot and leg (Rice, et al. 2014). This 
increases mechanical stress during ambulation, unnoticed injuries, structural foot deformity, 
such as hammertoes, bunions, metatarsal deformities, or Charcot foot leading to the formation 
of foot ulcerations (Rice, et al. 2014). In the 2006 NHMS III, prevalence of lower limb 
amputation among patients with diabetes was 4.3% (NHMS III, 2006). Foot ulcerations and 
amputations are major causes of morbidity and mortality in patients with diabetes.  
 
1.2.2 Ocular Effects  
DM can lead to several ocular complications such as DR, glaucoma, cataract, and ocular 
surface diseases. DR is the commonest major complication of DM and is currently the leading 
cause of preventable blindness in the developed countries (Klonoff and Schwartz, 2000; IDF 
and WHO, 2000). In Malaysia, the prevalence of DR from the 2007 Diabetic Eye Registry was 
36.8% (Goh, 2007), a similar prevalence in the Singapore Malay Eye Study 2006 (35%) was 
documented (Wong et al., 2008). Other unpublished data obtained from local primary care 
screening centers showed a combined prevalence ranging between 12.3% and 16.9% (Maziah 
et al., 2009; Kamilah et al., 2009). In patients with type 1 and type 2 diabetics with disease 
duration of over twenty years, the prevalences of DR are 95% and 60%, respectively (Garg and 
Davis, 2009). However, type 2 DM is responsible for a higher percentage of patients with visual 
loss (Kumari, et al. 2008). 
 
It is estimated that an approximately 1.5% of adults with diabetes have proliferative diabetic 
retinopathy (PDR) (Zhang et al., 2010). The DR study on the other hand showed that about 
half of all eyes with untreated PDR developed permanent vision loss (ie, visual acuity of 
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<20/800 for at least 4 months) due to serious complications such as tractional retinal 
detachment, vitreous hemorrhage, and neovascular glaucoma (DRS, 1979). PDR is 
characterized by retinal neovascularization, serum leakage, and fibrovascular proliferation. 
This results in vitreous hemorrhage and traction retinal detachment (Mazhar et al., 2011; Fong 
et al., 2004).  
 
Other complications include dry eye syndrome (DES) and diabetic keratopathy. DES is 
common in the diabetic population; 54% prevalence of asymptomatic and symptomatic DES 
(Manaviat et al., 2008). Chronic hyperglycemia, diabetic periphery neuropathy, decreased 
insulin levels, microvasculopathy, and systemic hyperosmotic disturbances are risk factors for 
diabetes-associated DES (Zhang et al., 2016). The severity of the dry eye disease also has been 
found to be correlated with the severity of DR (Nepp et al., 2000).  DM can trigger acceleration 
of ocular surface abnormalities which have been termed diabetic keratopathy (Schultz et al., 
1981). Several abnormalities have been shown in diabetic keratopathy. This includes thickened 
basement membrane, hemidesmosome alteration, increased epithelial fragility and decreased 
epithelial healing rates (Sanchez-Thorin, 1998). These abnormalities can lead to recurrent 
epithelial erosion (Schultz et al., 1981). 
 
Diabetic cataract is considered a complication of DM, diabetic patients are 2-5 times more at 
risk for cataract formation and are more likely to get it at an earlier age (Klein et al. 1995). 
Cataract formation in diabetics seems to be related to hyperglycemia and hastened senile lens 
opacity (Klein, et al. 1995). Several pathogenic mechanisms that may precipitate formation of 
diabetic cataracts are increased osmotic stress caused by activation of the polyol pathway, non-
enzymatic glycation of lens proteins, and increased oxidative stress (Srivastava, et al. 2005). 
A combination of cortical, nuclear, and posterior subcapsular cataract was the most common 
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form of the mixed cataract (20%), followed by the combined posterior subcapsular cataract and 
cortical (16%) (Raman, et al. 2010). 
 
1.3 Angiogenesis in Diabetes Mellitus  
Systemic vascular endothelial growth factor (VEGF) and the interplay between membrane-
bound VEGF receptors (R) and the soluble form of VEGF-R1 are key to angiogenesis, 
vasculogenesis, neurogenesis and hemodynamics (Wirostko et al., 2008). These cellular 
processes are regulated by complicated negative and positive feedback loops, many of which 
are disrupted and altered in diabetes (Wirostko et al., 2008). Mahdy et. al. (2010) revealed that 
there was a significant increase in the serum VEGF in the diabetic patients; the difference was 
between micro- and macrovascular diabetic complications compared with uncomplicated 
diabetic group. In addition, various cytokines, such as interleukin-6, insulin growth factors, 
advanced glycation end products including the VEGF, have been identified to play a role in the 
ocular angiogenesis and pathogenesis of DR (Singh et al., 2008; Mitamura et al., 2005; Shams 
et al., 2006). In the pathogenesis of PDR, the pro-angiogenic cytokine VEGF is considered the 
primary factor involved in neovascularization (Abu El-Asrar et al., 2013). Figure 2 summarizes 
the role of VEGF in the development of PDR. 
 
 
 
 
 
 
 
Figure 2. VEGF role in the development of PDR (Simó R et al., 2014) 
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1.3.1 Vascular Endothelial Growth Factor (VEGF)   
In 1983, Dvorak and colleagues discovered a key mediator involved in angiogenesis. It had a 
potent capacity to induce vascular leakage and was named vascular permeability factor (VPF) 
(Senger et al., 1983). Six years later, Ferrara and colleagues identified a similar molecule which 
promotes the proliferation of endothelial cells and called it VEGF (Ferrara et al., 1989). VEGF 
are a subfamily of growth factors that function as signaling proteins for both vasculogenesis 
and angiogenesis. Primarily, VEGF is secreted from retinal pigmented epithelial cells, 
pericytes, astrocytes, müller cells, glial cells, and endothelial cells (D’Amore 2007). VEGF has 
several members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth 
factor (PGF) (Gupta et al., 2013). Figure 3 depicts a VEGF molecule.  
 
 
Figure 3. VEGF isoforms molecular structure (Muller et al., 1998) 
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VEGF-A is a 36-46 kDa glycosylated protein derived by alternate splicing of messenger 
ribonucleic acid (mRNA) from a single, 8-exon VEGF gene (Tischer et al., 1991). The 
molecule is expressed as five mRNA splice variants – isoforms 121, 145, 165, 189, and 206, 
depending upon the number of amino acids present (Penn et al, 2008). VEGF 165 the principle 
isoform is critical for development and pathological angiogenesis as well as vasculogenesis 
(Shibuya 2013). VEGF acts by binding to VEGF R1, VEGF R2, and Neuropilin-1 receptor as 
it regulates vasculogenesis and leakage (Figure 4).  
 
 
 
Figure 4. Signaling pathways activated by VEGF (Yulong et al., 1999) 
 
Physiologically, VEGF is required for regulating the proliferation, migration, and survival of 
embryonic endothelial cells (Wang et al., 2008). However, in a disease state, it is involved in 
tumor development and vascular leakage (Yulong et al., 1999). Two independent studies 
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demonstrated that hypoxia could upregulate VEGF expression (Miller et al., 1994; Shweiki et 
al., 1992). It was found that higher level of VEGF in vitreous of patients with active diabetic 
proliferative retinopathies and venous occlusive disorders (Aiello et al., 1994). In addition, 
hypertension (Boursiquot et al., 2017), dyslipidemia (Zechariah et al., 2013) and smoking 
status (Ugur et al., 2018) are known factors affecting VEGF level. 
 
1.3.2 VEGF in Diabetic Retinopathy  
VEGF is an important factor in the development of both PDR and diabetic macular oedema by 
increasing the phosphorylation of proteins involved with tight-junctions such as zonula 
occludens and altering retinal capillary permeability (Simó et al., 2008; Antonetti et al., 1999).  
A study done by Alieo et al, suggested that VEGF in response to an ischemic state is as a 
primary initiator of PDR and as a potential mediator of non-proliferative diabetic retinopathy 
(NPDR) (Aiello et al., 2000).  Various studies on ocular VEGF levels have found a significant 
elevation in intraocular VEGF from the vitreous and aqueous samples. The level of VEGF also 
correlates with disease presence and its severity (Adamis et al., 2006; Aiello et al., 1994; 
Burgos et al., 1997).  
 
1.4 Ocular Tear Film 
The exposed part of the ocular globe is covered by a thin, fluid film - the preocular tear film. 
Tear film is comprised of three dynamic layers; mucin, aqueous and lipid. Contacting the 
corneal epithelium is a hydrophilic mucus layer approximately 0.02 to 0.05 µm.  As the 
underlying cornea itself is extremely hydrophobic, this layer is believed to provide a wetting 
substrate for the aqueous layer above it, which is about 6 to 9 µm thick (Holly and Lemp, 
1977). The most superficial is the lipid layer, which reduces tear evaporation (Creech et al., 
1998).  It also serves to protect against irritants, allergens, environmental extremes of dryness 
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and temperature, potential pathogens and pollutants. Tear components have antimicrobial 
function include lysozyme, lactoferrin, lipocalin, secretory immunoglobulin A (IgA) and 
complement (Lemp et al., 1970). Fleming and Allison (1922) also showed that lysozyme 
present in human tears can kill Gram-positive bacteria. This enzyme, which is secreted by the 
main and accessory lacrimal glands, accounts for up to 20–30% of total protein in both basal 
and reflex tears (Aho et al., 1996). Lactoferrin has a high capacity to bind divalent cations 
including iron thus depriving bacteria of this essential nutrient for growth and production of 
some toxins, although iron-independent antimicrobial actions (Farnaud and Evans, 2003). 
Secretory IgA is the major antibody present in the tear film. IgA is produced by plasma cells 
residing in the lacrimal gland and accessory lacrimal glands (Knop and Knop, 2005). Thus, 
like lactoferrin, ocular surface IgA promotes the clearance of pathogens (Mantis et al., 2011). 
Besides that, numerous functionally active complement factors are secreted by the lacrimal 
gland and distributed via the tears over the ocular surface (Klenker et al., 2007). Activation of 
the complement pathway generates fragments involved in acute inflammatory responses, 
fragments that act as opsonins, which facilitate formation of membrane attack complexes that 
can lyse pathogens (Willcox et al., 1997).  
 
1.4.1 Ocular Tear Film VEGF  
Till date there is no studies investigating VEGF levels in tear amongst patients with type 2 DM. 
Other studies have shown that tear VEGF level can increase in cases of retinal vein occlusion 
(RVO) patients, chronic extended contact user and corneal neovascularization disease (Kasza 
et al., 2015; Magone et al., 2004; van Setten, 1997). However, other inflammatory protein 
biomarkers have been studied. Tear proteins such as lipocalin 1, lactotransferrin, lacritin, 
lysozyme C, lipophilin A and immunoglobulin lambda chain were identified as possible 
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biomarker with significantly higher levels patients with DR (Csősz et al., 2012; Torok et al., 
2013). 
 
 1.4.2 Tear Sampling Techniques 
There are primarily 2 techniques use to collect tear sample. A cross-sectional study done on 
383 adult patients seeking for primary health care to evaluate whether tears could be used as 
tool for health screening. In this study, the pain score was elicited and compared between tear 
collection using Schirmer’s strips, previous experience of antecubital venous puncture and 
finger prick test. They found that the pain score for Schirmer’s tear collection was significantly 
lower than pain score for antecubital venous puncture. In addition, 70% agreed for their tears 
being collected to screen for eye problems (Quah et al., 2014). Therefore, to collect the human 
tear by using Schirmer’s strip is less invasive and less painful as compared to plasma collection. 
 
Glass capillary tube is another method for tears collection. The capillary tube is rested in the 
lateral tears meniscus and minimizes contact with bulbar conjunctiva (Lam et al., 2015). Tears 
are immediately collected by capillary tube. The average protein concentration obtained by the 
microcapillary tube showed the values was lower than the tears collection by schirmer strip 
(Farias et al., 2013). However, Choy et al suggested that capillary tube for human tears 
collection was less invasive as compared with schirmer strip (Choy et al., 2011). Nevertheless, 
human tears are relatively easier to be collected simultaneously from eyes by using Schirmer’s 
strip and it’s convenient as well.  
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Rationale of the study  
DR remains a major cause of worldwide preventable blindness. The microvasculature of the 
retina responds to hyperglycemia through several biochemical changes. VEGF has been 
postulated to also play a role in the pathogenesis and progression of DR (Aiello et al., 2000; 
Adamis et al., 2006). Previous studies evaluating the VEGF levels in the serum of DR patients 
have reported conflicting results (Guo et al., 2014; Deguchi et al., 2009; Ozturk et al., 2009; 
Fadhil, 2012). Serum levels of VEGF may be affected by the presence of other systemic illness 
which is common in diabetics (Yulong et al., 1999; Papaioannou et al., 2009). Identification 
of the serum VEGF might not reflect the changes in the retina due to the relatively small size 
of affected tissue such as retina and amount of the biomarker released in the large circulating 
blood volume (Nath et al., 2017). Hence, identification and quantification of VEGF in ocular 
disease may needs highly sensitive assay systems. 
 
Quantification of VEGF level in the ocular tissue, i.e. the aqueous or vitreous, may be more 
representative of DR. This is because VEGF levels in vitreous or aqueous are in close proximity 
to the retinal itself and better reflecting the pathophysiological process. However, measurement 
of aqueous or vitreous VEGF levels is relatively invasive and is associated with all the 
antecedent risks of surgical complication. Thus, aqueous and vitreous collection is only 
ethically possible if performed during surgical intervention such as cataract and vitreoretinal 
surgery. Studies has showed that VEGF were found in epithelial structures of the eye, such as 
cornea epithelium, ciliary epithelium, lens epithelium and retinal pigment epithelium (Setten 
et al., 1997; Ford et al., 2012). VEGF in tears may reflect the VEGF level in cornea epithelium 
because cornea epithelium is directly in contact with tears and is continuously debrided into 
tears due to turn over process. Tear fluid might contain VEGF from epithelial cells covering 
the eye surface. Furthermore, VEGF normally residing in the blood can get into the tear fluid 
 14 
 
 
through increased permeability of the conjunctival vessels (Zhou et al., 2009). Similarly, VEGF 
level in aqueous and vitreous may be closely similar to VEGF level in retina. Increased VEGF 
levels has been reported in the aqueous and vitreous fluid samples in DR patients (Adamis et 
al., 2006; Aiello et al., 1994; Burgos et al., 1997). The levels of VEGF also correlate with 
disease presence and its severity. Thus, VEGF levels in tears may reflect the severity of the DR 
progression in the retina.  
 
Although tear analysis is of increasing interest in ophthalmology, yet no studies have 
investigated tear VEGF levels in relation to the ischemic process and hence the severity of DR.  
Detection of VEGF levels in tears may thus be a less invasive, safe and acceptable method of 
screening DR. This might also act as a predictor for the severity of DR and to identifying 
patients who are at increased risk of progression from NPDR to PDR.  
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